

Resource Summary Report

Generated by [dkNET](#) on Sep 12, 2026

SU-DHL-5

RRID:CVCL_1735

Type: Cell Line

Proper Citation

ATCC Cat# CRL-2958, RRID:CVCL_1735

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1735

Proper Citation: ATCC Cat# CRL-2958, RRID:CVCL_1735

Description: Cell line SU-DHL-5 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Diffuse large B-cell lymphoma germinal center B-cell type

Defining Citation: [PMID:83902](#), [PMID:177185](#), [PMID:214220](#), [PMID:371794](#), [PMID:3881165](#), [PMID:8547074](#), [PMID:9787181](#), [PMID:10676951](#), [PMID:19278952](#), [PMID:20215515](#), [PMID:20628145](#), [PMID:22460905](#), [PMID:25355872](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:26727417](#), [PMID:27397505](#), [PMID:27566572](#), [PMID:28196595](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#)

Comments: Characteristics: Genetically heterogeneous, consists of 2 subclones (PubMed=27566572)., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SU-DHL-5

Synonyms: Su-DHL-5, SUDHL5, SUDHL-5, SU-DH-L5, SuDHL 5, Stanford University-Diffuse Histiocytic Lymphoma-5, DHL-5, DHL5

Cross References: CLO:CLO_0037062, EFO:EFO_0002356, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610,

ArrayExpress:E-MTAB-4956, ATCC:CRL-2958, BioGRID_ORCS_Cell_line:1025, BioSample:SAMN03472762, BioSample:SAMN10989557, cancercelllines:CVCL_1735, Cell_Model_Passport:SIDM00406, ChEMBL-Cells:ChEMBL4523530, ChEMBL-Targets:ChEMBL4523561, Cosmic:850204, Cosmic:1079255, Cosmic:1517657, Cosmic:1541910, Cosmic:2276339, Cosmic:2361380, Cosmic:2437314, Cosmic-CLP:1331036, DepMap:ACH-000660, DSMZ:ACC-571, DSMZCellDive:ACC-571, EGA:EGAS000001000610, EGA:EGAS000001000978, EGA:EGAS000001002554, GDSC:1331036, GEO:GSM1962, GEO:GSM380146, GEO:GSM552464, GEO:GSM887654, GEO:GSM888746, GEO:GSM1035317, GEO:GSM1151287, GEO:GSM1374907, GEO:GSM1670486, IARC_TP53:30173, IGRhCellID:SUDHL5, LiGeA:CCLE_716, LINCS_LDP:LCL-1137, PharmacoDB:SUDHL5_1503_2019, Progenetix:CVCL_1735, PubChem_Cell_line:CVCL_1735, Wikidata:Q54970720

ID: CVCL_1735

Vendor: ATCC

Catalog Number: CRL-2958

Record Creation Time: 20220427T221612+0000

Record Last Update: 20260905T182514+0000

Ratings and Alerts

No rating or validation information has been found for SU-DHL-5.

No alerts have been found for SU-DHL-5.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Enssle JC, et al. (2026) Pathogenesis of diffuse large B cell lymphoma proteogenotypes. Cancer cell, 44(7), 1437.

S Mesquita F, et al. (2025) Identification of a lipid oxygen radical defense pathway and its epigenetic control. Nature communications, 17(1), 696.

Rossi A, et al. (2025) Downregulation of rRNA synthesis by BCL-2 induces chemoresistance in diffuse large B cell lymphoma. iScience, 28(5), 112333.

L????nd F, et al. (2025) DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response. Blood

cancer discovery, 6(6), 580.

He MY, et al. (2024) GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma. *Leukemia*, 38(10), 2210.

Scuoppo C, et al. (2024) Repurposing NAMPT Inhibitors for Germinal Center B Cell-Like Diffuse Large B-Cell Lymphoma. *Blood cancer discovery*, 5(6), 417.

McCrury M, et al. (2024) Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma. *Molecular cancer therapeutics*, 23(3), 316.

Choi J, et al. (2024) Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. *Cancer cell*, 42(5), 833.

Bolomsky A, et al. (2024) IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. *Cancer cell*, 42(7), 1185.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. *Cancer research communications*, 3(4), 576.

Scheich S, et al. (2023) Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas. *Cancer discovery*, 13(8), 1862.

Kreer C, et al. (2023) Probabilities of developing HIV-1 bNAb sequence features in uninfected and chronically infected individuals. *Nature communications*, 14(1), 7137.

Roider T, et al. (2021) The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial. *International journal of cancer*, 148(1), 150.

Dersh D, et al. (2021) Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas. *Immunity*, 54(1), 116.

Dufva O, et al. (2020) Immunogenomic Landscape of Hematological Malignancies. *Cancer cell*, 38(3), 380.

Liang K, et al. (2017) Therapeutic Targeting of MLL Degradation Pathways in MLL-Rearranged Leukemia. *Cell*, 168(1-2), 59.